Quantum computing stocks are surging, fueled by excitement around AI and next-gen tech. IonQ, a standout name, is venturing into quantum medicine with a new partnership to accelerate therapeutics development. The company’s innovative trapped-ion approach is attracting big industry players. Despite recent volatility, IonQ’s stock has soared 951.8% in three years, with a market cap of $16.4 billion. IonQ’s Q3 earnings beat expectations, with revenue up 222% YOY. Analysts remain bullish on IonQ, with an average price target of $72.89, suggesting a potential 55.3% gain. Cantor Fitzgerald raised its price target to $70, seeing vast growth potential.

IonQ’s recent move into quantum medicine through a strategic partnership with CCRM aims to accelerate the development of advanced therapeutics using hybrid quantum and quantum-AI technologies. The company’s Q3 earnings report showed impressive revenue growth of 222% YOY, beating Wall Street expectations. With a strong financial position and a world-record 99.99% two-qubit gate fidelity achievement, IonQ is well-positioned in the quantum computing race. Analysts are optimistic about IonQ’s future, with a consensus rating of “Moderate Buy” and an average price target of $72.89, indicating a potential 55.3% upside.

Read more at Barchart: IonQ Wants to Bring Quantum Computing to Medicine. Should You Buy IONQ Stock Here?